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Recombinant adeno-associated viruses (rAAV) are among the most promising gene therapy delivery vectors for 
treating patients with genetic abnormalities. rAAV can safely deliver long-lasting expression of a therapeutic 
transgene to target cells. Multiple studies using rAAV have demonstrated sustained transgene expression in 
cultured cells and pre-clinical models, suggesting that rAAV could provide a cure for certain diseases. Moreover, 
bioengineering advancements have expanded the viral tropism beyond the constraints of naturally occurring 
AAV capsids, increasing the cell types that can be thought of as targets. Taken together, rAAV therapies have 
attractive qualities to safely address the needs of patients where other modalities may fall short.  
 
One challenge with therapeutic rAAV is the ability to generate enough virus for clinical trials and commercial 
supply. This challenge is particularly true with neuromuscular or hemophilia patients in which doses can exceed 
1 x 1014 viral genomes per patient. Typical yields from a rAAV production are around 104 viral genomes per cell, 
meaning batch cell numbers would need to exceed 1010 for a single dose. These doses require a robust, 
scalable platform to generate quantities of rAAV to meet patient demand. Biogen has selected the producer cell 
line (PCL) platform to meet the large demand for therapeutic rAAV. A PCL is a stable cell line engineered to 
contain the ITR flanked transgene of interest and AAV sequences needed to produce rAAV upon addition of 
helper virus. We will present our rationale for selecting the PCL platform as a cost-effective manufacturing 
strategy for gene therapy programs as well as current technical improvements and our vision for the next 
generation PCL platform.  
 
 
 
